CTOs on the Move

AutoCruitment

www.autocruitment.com

 
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Institute for Therapy through the Arts

The Institute for Therapy through the Arts offers art therapy, music therapy, dance therapy, and drama therapy in Evanston, IL 60201 and Chicagoland.

BestCo

BestCo is a leading developer and manufacturer of innovative pharmaceutical dosage forms for the OTC (Over-the-Counter) Drug, Vitamin and Supplement marketplace.

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AlphaRx

AlphaRx, Inc. is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.